Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy, April 23, 2025, 11:30 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical
Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy, April 1, 2025, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical
Ad hoc announcement pursuant to Art. 53 LR
Expected to succeed Dr. Ulrich Köstlin who has notified Newron of his intention to retire after 12 years of service as Chairman of its
Milan, Italy and Morristown, NJ, USA – March 11, 2025 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused
Newron and Myung In Pharm announce license agreement for evenamide in South Korea
Myung In Pharm to develop, manufacture and commercialize evenamide in South Korea
Myung In Pharm
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
